A readily available over-the-counter nasal spray, azelastine, is showing important potential as a preventative measure against respiratory infections, including‍ COVID-19. A recent clinical trial involving 450 participants demonstrated a remarkable reduction in SARS-cov-2 infections among those using the spray.

The study, a randomized, double-blind, placebo-controlled trial, divided ⁤participants into two groups.Over a 56-day period, 227 individuals used azelastine nasal spray three times daily,‍ while the remaining 223 used a placebo spray with the same frequency. The results were striking: only 2.2% of the azelastine group contracted COVID-19, compared to 6.7% in the placebo ⁢group – a threefold difference. All infections were confirmed through rigorous⁢ PCR testing.

But the benefits didn’t stop there. Researchers observed fewer symptomatic COVID-19 cases and a⁣ lower overall incidence of all confirmed ⁣respiratory infections in the‍ azelastine group. perhaps surprisingly, the spray also considerably⁤ reduced rhinovirus⁢ infections – the common cold – with just ⁣1.8% of the treatment ‍group contracting the virus versus 6.3% in the ⁣placebo group, mirroring the ⁣protection seen against SARS-CoV-2.

Azelastine has long been used to treat hay fever, and laboratory studies had previously hinted at its antiviral properties. This new research marks the first time a protective effect has been demonstrated in a real-world clinical setting.

While further ⁢research is ⁣needed, these findings ⁣suggest azelastine nasal spray could become a‍ valuable tool in protecting vulnerable populations, particularly during periods of high infection rates or before travel. Researchers⁣ emphasize the need for larger, multi-center trials to explore⁤ its potential as ⁤an “on-demand” preventative treatment and ‍to assess its effectiveness against a wider range of⁢ respiratory pathogens.

This collaborative effort involved researchers from multiple institutions, including the Department of Internal Medicine V at Saarland University medical Center, the Institute of Clinical Pharmacy, the Institute of Virology, and the pharmaceutical company URSAPHARM Arzneimittel GmbH, highlighting the power of partnerships between academia,⁢ industry, and public health initiatives.